Published on :
A patch once morest the Covid. The hypothesis is currently under study in Switzerland where researchers are testing a new vaccine. Easier to administer and perhaps more effective once morest variants, this is the bet, in any case, of the British biotech Emergex, which has just launched clinical trials in Lausanne.
With our correspondent in Switzerland, Jeremiah Lanche
« It burns a little bit more… Afterwards, it’s quite tolerable “The first volunteer to receive the anti-Covid vaccine as a patch can attest to this: for the painless side, we will come back. But the essential is elsewhere. The vaccine should help develop cellular immunity. Considered to be more effective once morest variants.
« Messenger RNA vaccines significantly stimulate the production of antibodies, while our vaccine, here, the primary goal is to stimulate what is called the cellular immune response, which is an immunity that lasts over the long term and which, we hope, helps protect severe forms of Covid », Explains Alix Miauton, head of clinic at Unisanté, the organization in charge of the trials.
► To listen also: Omicron: the global outbreak
In anticipation of a new pandemic …
More effective, longer, the patch vaccine is not yet there to replace RNA vaccines, already very effective once morest severe forms of the disease. But it might come in addition to the products already available. This will require that the tests confirm its effectiveness.
No commercialization is expected before 2025. But even if the pandemic had disappeared in the meantime, the vaccine and patch might prove very useful if a new one were to be triggered.
► To read also: Covid-19 and children: what do we know two years following the start of the pandemic?
.
